19 reports of this reaction
3.1% of all ARFORMOTEROL TARTRATE reports
#3 most reported adverse reaction
PNEUMONIA is the #3 most commonly reported adverse reaction for ARFORMOTEROL TARTRATE, manufactured by Alembic Pharmaceuticals Inc.. There are 19 FDA adverse event reports linking ARFORMOTEROL TARTRATE to PNEUMONIA. This represents approximately 3.1% of all 613 adverse event reports for this drug.
Patients taking ARFORMOTEROL TARTRATE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is moderately reported among ARFORMOTEROL TARTRATE users, representing a notable but not dominant share of adverse events.
In addition to pneumonia, the following adverse reactions have been reported for ARFORMOTEROL TARTRATE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 19 FDA reports for ARFORMOTEROL TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 3.1% of all adverse event reports for ARFORMOTEROL TARTRATE, making it one of the most commonly reported side effect.
If you experience pneumonia while taking ARFORMOTEROL TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.